Skip to main content

Merck and Isomorphic Labs agree research deal on new cancer drugs

Merck and Isomorphic Labs said they are entering into a research collaboration to discover small molecule candidates in oncology, according to STAT. No financial terms or specific targets were disclosed in the announcement.

This move signals another large pharma company seeking external innovation in cancer drug discovery. For pharma and biotech leaders, this may mean more competition for partnerships and a shift in how oncology pipelines are built. Further information on the collaboration’s scope will be important for assessing its impact.

Stat

Find out more here